Martínez-Carrillo Miguel, Tovar-Martín Isabel, Zurita-Herrera Mercedes, Del Moral-Ávila Rosario, Guerrero-Tejada Rosario, Saura-Rojas Enrique, Osorio-Ceballos Juan Luis, Arrebola-Moreno Juan Pedro, Expósito-Hernández José
Radiation Oncology Department, Virgen de las Nieves University Hospital, 18014 Granada, Spain.
Neurosurgery Department, Virgen de las Nieves University Hospital, 18014 Granada, Spain.
Biomed Res Int. 2014;2014:657953. doi: 10.1155/2014/657953. Epub 2014 May 7.
To analyse the survival after salvage radiosurgery and to identify prognostic factors.
We retrospectively reviewed 87 consecutive patients, with recurrent high-grade glioma, that underwent stereotactic radiosurgery between 1997 and 2010. We evaluated the survival after initial diagnosis and after reirradiation. The prognostic factors were analysed by bivariate and multivariate Cox regression model.
The median age was 48 years old. The primary histology included anaplastic astrocytoma (47%) and glioblastoma (53%). A margin dose of 18 Gy was administered in the majority of cases (74%). The median survival after initial diagnosis was 21 months (39 months for anaplastic astrocytoma and 18.5 months for glioblastoma) and after reirradiation it was 10 months (17 months for anaplastic astrocytoma and 7.5 months for glioblastoma). In the bivariate analyses, the prognostic factors significantly associated with survival after reirradiation were age, tumour and treatment volume at recurrence, recursive partitioning analyses classification, Karnofsky performance score, histology, and margin to the planning target volume. Only the last four showed significant association in the multivariate analyses.
stereotactic radiosurgery is a safe and may be an effective treatment option for selected patients diagnosed with recurrent high-grade glioma. The identified prognostic factors could help individualise the treatment.
分析挽救性放射外科治疗后的生存率并确定预后因素。
我们回顾性分析了1997年至2010年间连续87例接受立体定向放射外科治疗的复发性高级别胶质瘤患者。我们评估了初始诊断后及再次放疗后的生存率。通过双变量和多变量Cox回归模型分析预后因素。
中位年龄为48岁。原发组织学类型包括间变性星形细胞瘤(47%)和胶质母细胞瘤(53%)。大多数病例(74%)给予的边缘剂量为18 Gy。初始诊断后的中位生存期为21个月(间变性星形细胞瘤为39个月,胶质母细胞瘤为18.5个月),再次放疗后的中位生存期为10个月(间变性星形细胞瘤为17个月,胶质母细胞瘤为7.5个月)。在双变量分析中,与再次放疗后生存率显著相关的预后因素包括年龄、复发时的肿瘤和治疗体积、递归分区分析分类、卡诺夫斯基表现评分、组织学类型以及到计划靶体积的边缘。在多变量分析中,仅最后四项显示出显著相关性。
立体定向放射外科治疗对于确诊为复发性高级别胶质瘤的特定患者是一种安全且可能有效的治疗选择。所确定的预后因素有助于实现个体化治疗。